Stories Category Subscribe to RSS Feed

Clopidogrel in CYP2C19 poor metabolizers: Four-fold dose increase may be needed

Published: Aug 31st, 2014

Clopidogrel is an antiplatelet agent that is bioactivated through a two-step process involving the polymorphic CYP2C19 enzyme. CYP2C19 genotype can be used to predict clopidogrel response, particularly in patients undergoing […]

CYP2D6 drug interactions and response to hydrocodone, ondansetron

Published: Aug 24th, 2014

Joseph Ladd, University of Florida College of Pharmacy 2015 PharmD Candidate The CYP2D6 enzyme is involved in the metabolism of roughly 25% of all medications, including codeine, hydrocodone, oxycodone, and […]

New position statements give guidance on personalized medicine in cardiology, oncology

Published: Aug 15th, 2014

Two recently published position papers from the European Society of Cardiology (ESC) and the European Society for Medical Oncology (ESMO) summarized the current state of personalized medicine, future challenges, and […]

Bridging the pharmacogenomics knowledge gap: Study reveals current needs, strategies

Published: Jul 30th, 2014

Teresa Vo, PharmD According to a recent survey of primary care physicians, cardiologists, and psychiatrists, nearly 20% of respondents reported ordering a pharmacogenetic test in the previous year. Respondents expressed […]

Updated SLCO1B1–simvastatin guideline provides resources to support clinical implementation

Published: Jul 25th, 2014

Nathan Seligson (University of South Florida College of Pharmacy PharmD Candidate, Class of 2015) An updated Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 (alternative names include OATP1B1, OATP-C) and […]

Meta-analysis of genotype-guided warfarin trials yields disappointing results

Published: Jun 30th, 2014

A meta-analysis of randomized clinical trials found that genotype-guided dosing of warfarin, acenocoumarol, or phenprocoumon did not result in a greater percentage of patients with international normalized ratio (INR) in […]

CYP2C19 genotype variability: Effects on voriconazole and metabolite levels

Published: Jun 15th, 2014

Teresa Vo, PharmD, 2013-2014 PGY2 Resident in Personalized Medicine In a prospective evaluation of 95 patients treated with voriconazole (Vfend—Pfizer) over a 2-year period, CYP2C19 and CYP2C9 genotypes were not […]

Clopidogrel: CYP2C19, CYP1A2 effects in some post-MI patients

Published: Jun 1st, 2014

Daniel Zambrano (University of Florida College of Pharmacy PharmD Candidate, Class of 2015)   A recent large study showed associations between both loss-of-function and gain-of-function CYP polymorphisms and poor outcomes […]

Drug interactions, pharmacogenetics influence codeine, morphine levels

Published: May 28th, 2014

Ben Kong, PharmD   In an analysis of codeine-related deaths, drug interactions and genetic polymorphisms were significantly associated with changes in post-mortem morphine-to-codeine ratios. Specifically, genetic variability in ABCB1, but […]

Preemptive genotyping: More than 90% of patients have actionable result

Published: May 15th, 2014

Out of approximately 10,000 patients genotyped in the Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment (PREDICT) program at Vanderbilt University Medical Center, 91% had at least one actionable […]